To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma
Age≥65 years old
Histologically confirmed primary cervical squamous cell carcinoma in stage IB3-IVA (FIGO 2018)
At least one measurable lesion according to RECIST 1.1 guideline
Patients are intolerant to or refuse chemotherapy.
Patients who have received treatment for cervical cancer, including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy
Patients who have bilateral ureteral obstruction, who cannot be placed ureteral stents or perform pyelostomy.
Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding or with fistula risk.
Peking University Third Hospital
Lead sponsor